Key Players
Competitive Landscape
Key Players
Viome Life Sciences, 23andMe Research Institute (TTAM Research Institute), Tiny Health, Nutrigenomix Inc., Mapmygenome India Ltd. and Xcode Life Sciences Pvt. Ltd. are covered in the competitive discussion.
Table 7: Company Developments and Commercial Implications
| Evidence | Commercial effect | Buyer action |
|---|---|---|
| TTAM Research Institute wins court approval to buy 23andMe for USD 305 million, 27 June 2025 | The best-known consumer genetics brand continues under nonprofit ownership with extra privacy terms. | Partners and supplement brands should check data-sharing terms before linking to its reports. |
| Viome and Ezaki Glico launch a gut mRNA health tracker in Japan, September 2026 | A US testing brand enters Japan through a major food company. | Asian supplement and food firms should explore data-linked product partnerships. |
| Viome acquires Solaria Bio, October 2026 | Testing is linked to clinically studied medical foods sold without a test. | Retail pharmacies should review whether such products fit their category plans. |
| Tiny Health announces a USD 5 million Microbiome Research Program, 29 September 2026 | Researchers and clinicians gain access to its testing and data for interventional studies. | Clinics and researchers should assess whether the program fits their study designs. |
How are the companies positioned?
Viome and Tiny Health focus on microbiome testing, and 23andMe on consumer genetics. Nutrigenomix, Mapmygenome and Xcode Life Sciences focus on DNA-based diet reports.
What matters when a buyer qualifies a nutrigenomic partner?
Buyers check test validation, data privacy terms, clinical evidence and regulatory status of claims. The 23andMe sale required enhanced privacy and consumer protection terms.
Which capabilities distinguish the product offers?
Clinical trials, proprietary data and bundled products distinguish the offers, and Viome combines its microbiome data with a medical food pipeline.
How does geographic reach affect competition?
Local partners matter, as Viome entered Japan with Ezaki Glico, and Mapmygenome serves Indian customers from accredited laboratories.
Representative Company Overview
Table 8: Nutrigenomic Market Representative Company Overview
| Company | Positioning | Verified activity |
|---|---|---|
| Viome Life Sciences | RNA-based microbiome testing and personalized nutrition company | Acquired Solaria Bio in October 2026 and launched a gut mRNA health tracker in Japan with Ezaki Glico in September 2026. |
| 23andMe Research Institute (TTAM Research Institute) | Consumer genetics company owned by a nonprofit since 2025 | Bought 23andMe's assets for USD 305 million, with court approval on 27 June 2025. |
| Tiny Health | US microbiome testing company | Offers gut microbiome tests for babies, children and adults and announced a USD 5 million Microbiome Research Program on 29 September 2026. |
| Nutrigenomix Inc. | Genetic tests for personalized nutrition sold through practitioners | Reports more than 12,000 practitioners in 95 countries. |
| Mapmygenome India Ltd. | Indian genetic testing and wellness company | Sells at-home DNA, gut and epigenome kits processed in CAP and NABL-accredited laboratories. |
| Xcode Life Sciences Pvt. Ltd. | Genetic report provider that analyses uploaded DNA files | Offers 11 reports from uploaded raw DNA data and ships no kits. |
Research Methodology
The nutrigenomic market assessment was conducted using primary interviews and secondary literature analysis combined with top-down data triangulation to validate market size, segment shares, and competitive positioning.